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Abstract: 
Although the concept of Reverse Vaccinology was first pioneered for sepsis and meningococcal meningitidis causing bacterium, Neisseria meningitides, no 
broadly effective vaccine against serogroup B meningococcal disease is yet available. In the present investigation, HLA distribution analysis was undertaken to 
select three most promiscuous T-cell epitopes out of ten computationally validated epitopes of Iron acquisition proteins from Neisseria MC58 by using the 
population coverage tool of Immune Epitope Database (IEDB). These epitopes have been determined on the basis of their binding ability with maximum number 
of HLA alleles along with highest population coverage rate values for all the geographical areas studied. The comparative population coverage analysis of 
moderately immunogenic and high immunogenic peptides suggests that the former may activate T-cell response in a fairly large proportion of people in most 
geographical areas, thus indicating their potential for development of epitope-based vaccine. 
 
 
Keywords: Neisseria meningitidis, Population Coverage, T cell epitopes, Immune Epitope Database. 
 
 
 
 
Background: 
The availability of a large and ever increasing volume of microbial genomic 
information have brought forth Reverse Vaccinology as a faster and cheaper 
approach to design vaccines in vivo compared to traditional empirical methods. 
Serogroup B meningococcus represents the first example of the successful 
application of Reverse Vaccinology [1]. Invasive meningococcal disease is 
now endemic worldwide and most cases are caused by five of the thirteen 
meningococcal subgroups A, B, C, Y and W135 [2]. Serogroup B is the main 
cause of invasive meningococcal disease in most temperate countries and 
accounts for 32% of all meningococcal disease cases in the United States, 45-
80% of the cases in Europe and more than 50% of the cases in the rest of the 
world  [3, 4]. Applications of new approaches for vaccine design including 
genome mining [5-9] and proteomics [10, 11] have identified several vaccine 
targets against Men B as listed in Table 1 (see Supplementary material) [12-
37]. However, the vaccine potential of nearly all of these candidates has been 
limited either by antigenic variables, phase variability, presence of auto 
antigens or low constitutive expression of the antigen by some strains [38]. 
Hence, the development of a universally safe and effective serogroup B 
Neisseria meningitidis vaccine still remains a challenge for researchers. T-cell 
recognises a complex between a specific major histocompatibility complex 
(MHC) molecules and a particular pathogen derived epitope [39]. MHC 
molecules are highly polymorphic. Till date, in human more than 225 HLA 
Class I and 986 HLA Class II allelic sequences have been identified [40]. This 
polymorphism is concentrated in the region encoding the peptide-binding 
groove of HLA molecules and as a result, MHC molecules exhibit a widely 
varying binding specificity. Moreover, in the design of epitope-based vaccines, 
the issue of population coverage in relation to MHC polymorphism is further 
complicated by the fact that frequency of expression of different HLA types 
varies in different ethnicities [39]. Thus the main desirable characteristics for 
meningococcal vaccine candidate is that the selected epitopes should elicit T-
cell immune response and that they should bind to several alleles of HLA super 
type for maximal population coverage. In the present study an effort has been 
made to perform population coverage analysis of total ten promiscuous T-cell 
epitopes (Class I and Class II) of Iron acquisition proteins (FrpB; Acc no NMB 
1988 and FbpA; Acc no NMB0634) that has been computationally validated 
using different immunoinformatics tools to elicit immune response against the 
pathogen  Neisseria meningitidis MC58 [41]. The resultant epitopes of the 
present study would be a relevant representative of a large proportion of human 
population. 
 
Methodology: 
HLA Distribution Analysis: 
In order to determine the population coverage rate of the computationally 
validated ten promiscuous high or moderate immunogenic T- cell epitopes, the 
predicted putative epitopic core sequences with the corresponding HLA alleles 
(Class I and Class II) were submitted to the population coverage analysis tool BIOINFORMATION  open access 
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of the Immune Epitope Database (IEDB) [39] by keeping the default 
parameters on (Population/Area= 78 populations grouped into 11 different 
geographical areas). Population coverage analysis tool calculates the fraction of 
individuals predicted to respond to a given set of epitopes with known MHC 
restrictions. For individual population coverage, the tool computes the 
following: (1) projected population coverage, (2) average number of epitope 
hits/ HLA combinations recognised by the populations and (3) minimum 
number of epitope hits/ HLA combinations recognised by 90% of the 
population (PC90). These calculations are made on the basis of HLA genotypic 
frequencies assuming non-linkage disequilibrium between HLA loci. 
 
Blast Screening: 
In order to avoid generation of auto immune disease the final epitopic core 
sequences showing affinity  to maximum number of HLA molecules with high 
population rates were searched against the human proteome using HLAPred 
tool [42]. 
 
 
Figure 1: HLA binding affinity for the putative promiscuous T-cell epitopes of 
FrpB and FbpA proteins. 
 
Results and Discussion: 
Population coverage analysis plays an important role for the design of peptide 
based vaccine. The frequency of expression of different HLA types varies in 
different ethnicities as the MHC molecule is highly polymorphic [43, 44]. 
Extreme polymorphism restricts the proportion of the human population that 
may respond to a particular antigen [45, 46]. Thus a peptide which functions as 
T-cell epitope in a population with certain HLA make up may not be effective 
in another population with a different HLA allelic distribution. The aim of the 
study was to select promiscuous T-cell epitopes that bind to several alleles of 
HLA super types for maximal population coverage. 
 
The population coverage rate of the predicted epitopes of Neisseria 
meningitidis Iron acquisition proteins (FrpB and FbpA) were analyzed  by 
submitting the promiscuous epitopic core sequences (Class I and class II) with 
their corresponding HLA alleles to IEDB population coverage analysis tool. A 
total of 27 alleles were shared by all the epitopes and approximately 90 alleles 
bind to maximum number of peptides (Table 4 & 5 see Supplementary 
material). The IEDB results reveal a strong positive correlation between HLA 
binding affinity and population coverage rate among the peptides.  For example 
the peptides 
148KTVDAQDLLK
157 and 
60ATDMRELLK
68 with maximum 
(83.13%) and minimum (59.55%) population coverage rate were found to be 
correlated with highest (121 HLA alleles) and lowest (62 HLA alleles) HLA 
binding epitopes, respectively. However, similar type of correlation does not 
exist among the moderately predicted epitopes (
44RATGIKVKL
52 and 
488HGKRGSII
496). Interestingly, these epitopes, although exhibited to bind with 
lower number of HLA alleles in comparison to high immunogenic peptide, 
elicit wider population coverage rate (Figure 1, Table 2 & Table 3 see 
Supplementary material). In order to further pin-point the most potential 
epitopes comparative HLA distribution analysis was preformed and the values 
of two moderate and five high immunogenic epitopes indicates that the former 
are equally potential candidates for vaccine design (Figure 2). Finally three 
epitopes have been conclusively selected one each from moderate 
immunogenic (
44RATGIKVKL
52) and high immunogenic 
(
148KTVDAQDLLK
157) Class I epitopes and one from Class II epitopes 
(
629VQKAVGSILVAG
643), on the basis of high population coverage rate and 
maximum affinity to HLA alleles. These epitopes exhibited coverage rates 
exceeding 99% in five ethnic groups and between 96 to 98% for six other 
ethnic groups (Figure 3). Maximum population coverage rate (99.79%) was 
observed in Europe indicating that a future vaccine based on these putative 
epitopes might work most efficiently for majority of population in Europe 
where the incidence of Meningococcal disease is highest (> 90%) [47].  
 
 
Figure 2: Comparative Population coverage rate analysis between Moderate 
(RATGIKVKL and HGKRGSII) and High (EKDLEKSVL, DAQDLLKGL, 
ATDMRELLK, KFVAFLASK, KTVDAQDLLK and LVKVVSVQK) 
immunogenic peptides. 
 
 
Figure 3: Predicted population coverage rate (%) of final selected three 
promiscuous T-cell epitopes viz RATGIKVKL, KTVDAQDLLK (Class I) and 
VQKAVGSILVAG (Class II) of FrpB and FbpA MenB proteins 
 
Conclusion: 
Vaccination programs are the most versatile means of prophylactic infectious 
diseases control majors for vulnerable human population. Immunoinformatic 
epitope-based vaccine development approach using computational tools, 
databases and web servers is time and cost effective as compared to traditional 
laboratory experiments. In the present investigation three promiscuous putative 
epitopes viz., 
148KTVDAQDLLK
157, 
44RATGIKVKL
52 and 
629VQKAVGSILVAG
640 from iron acquisition proteins (FrpB and FbpA) have 
been computationally validated as potential MenB vaccine candidates across 
diverse ethnicities. This study may stimulate further in vitro investigations to 
ascertain the immunogenicity of these putative epitopes for designing effective 
vaccines against Neisseria meningitidis serogroup B. 
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Supplementary material: 
 
Table 1: Meningococcal serogroup B vaccines investigated in Clinical trials 
Components/Vaccine   References 
B polysaccharide   [12] 
N-propionylated B polysaccharide  [13] 
Outer membrane protein and B polysaccharide   [14] 
Outer membrane vesicle, C polysaccharide and 65-95KDa enveloped proteins   [15], [16], [17] 
Outer membrane vesicle   [18-24] 
Outer membrane protein and C polysaccharide   [25-30] 
Bivalent Outer membrane vesicle   [31, 32] 
Intranasal Outer membrane vesicle   [33-35] 
NspA    [36] 
2fusion proteins, GNA 2091-fHbp variant1 and GNA 2132-GNA1030 and NadA  [37] 
 
Table 2: Population coverage rate (%) of MHC Class Ι peptides as predicted by IEDB server 
 Population  Coverage  rate 
Population/Area EKDLEKSVL  RATGIKVKL  KFVAFLASK  LVKVVSVQK  KTVDAQDLLK  DAQDLLKGL  ATDMRELLK  HGKRKIISI 
Australia  90.70 92.68 91.22 78.71  91.49  91.42 65.44 92.38 
Europe  97.21 99.03 98.50 98.07  99.28  98.95 81.34 97.51 
North  Africa 53.30 62.67 59.70 48.94  61.69  56.21 16.67 65.70 
North  America  97.07 98.51 98.14 90.77  98.35  97.66 86.40 96.75 
North  East  Asia  86.25 89.87 90.35 87.41  93.11  91.15 58.81 91.54 
Oceania  95.08 96.13 95.19 86.16  95.61  94.86 70.12 96.64 
Other  95.73 96.92 96.87 95.32  97.81  96.75 75.05 95.52 
South  America  89.33 92.09 92.04 91.92  92.31  92.27 83.23 86.88 
South  East  Asia  92.84 95.54 93.51 89.59  96.89  95.68 71.21 95.99 
South  West  Asia  92.71 92.42 94.91 93.99  95.46  93.78 55.62 94.15 
Sub-Saharan  Africa  86.24 87.16 87.02 89.37  91.49  89.42 48.09 85.14 
AVERAGE  78.72 81.26 80.69 75.54  83.13  81.62 59.55 81.00 
Standard  Deviation  30.30 29.25 29.22 29.00  29.31  29.32 28.29 28.99 
 
Table 3: Population coverage rate (%) of MHC Class ΙI peptides as predicted by IEDB server. 
  Population coverage rate (%) 
Population/Area  KPYAKNSVALQAV VQKAVGSILVAG 
Australia 43.75  47.95 
Europe 43.53  52.92 
North Africa  67.90  78.74 
North America  38.52  36.57 
North East Asia  71.54  76.15 
Oceania 61.80  65.97 
Other 67.88  79.47 
South America  21.09  23.77 
South East Asia  16.04  16.95 
South West Asia  64.97  79.10 
Sub-Saharan Africa  44.82  62.01 
AVERAGE 24.41  27.92 
Standard Deviation  28.93  33.33 
 
Table 4: List of MHC Class I T-cell epitopes with their corresponding HLA alleles, as predicted by Syfpeithi, nHLAPred, ProPred1, NetCTL and immunogenicity 
by POPI , showing the selected 10-mer epitope 
148KTVDAQDLLK
157 (high) and 9-mer epitope 
44RATGIKVKL
52 (moderate) immunogenicity and that bind to 
maximum no. of HLA molecules obtained from FrpB and FbpA proteins  respectively. 
Sl. 
No 
Epitope core 
(9-mer) 
Protein 
(Acc.no) 
Amino 
Acid 
position 
Immunogenicity  
as predicted by 
POPI server 
Total No 
of  
binding 
HLA  
molecules 
HLA alleles predicted to bind to the epitope 
1 EKDLEKSVL  FbpA 
(NMB0634) 
136 High   
Immunogenic 
91  HLA A1, HLA A2, HLA A*0201, HLA A*0205, HLA A24, HLA 
A*3302, HLA A68.1, HLA A20, HLA A20Cw, HLA A2.1, HLA B14, 
HLA B*2702, HLA B*2705,HLA B*3501, HLA B*3701, HLA 
B*3801, HLA B*3901, HLA B*3902, HLA B40, HLA B*4403, HLA 
B*5101, HLA B*5102, HLA B*5103, HLA B*5201, HLA B*5801, 
HLA B60, HLA B61, HLA B7, HLA B*0702, HLA B8, HLA 
Cw*0301, HLA Cw*0401, HLA Cw*0602, HLA Cw*0702, HLA 
A*26, HLA B*3902, HLA B*4401, HLA A*0111, HLA A*0201, HLA 
A*03, HLA A*1101, HLA A*2402, HLA A*26, HLA B*0602, HLA 
B*1402, HLA B*1510, HLA B*18, HLA B*2705, HLA B*3801, HLA 
B*3901, HLA B*3902, HLA A*2601, HLA A*2602, HLA A*2603, 
HLA A*2605, HLA A*2606, HLA A*2608, HLA A*2609, HLA 
A*2611, HLA A*2612, HLA A*2618, BIOINFORMATION  open access 
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            HLA B*0801, HLA B*0803, HLA B*0804, HLA B*0805, HLA B*39, 
HLA B*3902, HLA B*3903, HLA B*3905, HLA-B*3906, HLA-
B*3907, HLA-B*3908, HLA-B*3910, HLA-B*3911, HLA-B*3913, 
HLA B*3915, HLA B*2702, HLA B*2703, HLA B*2704, HLA 
B*2705, HLA B*2706, HLA B*2707, HLA B*2709, HLA B*2711, 
HLA B*2714, HLA B*4701, HLA B*4901 
2 RATGIKVKL  FbpA 
(NMB0634) 
44 Moderate 
Immunogenic 
91  HLA A1, HLA A2, HLA A*0201, HLA A*0205, HLA A24, HLA 
A*3302, HLA A68.1, HLA A20, HLA A20Cw, HLA A2.1, HLA B14, 
HLA B*2702, HLA B*2705,HLA B*3501, HLA B*3701, HLA 
B*3801, HLA B*3901, HLA B*3902, HLA B40, HLA B*4403, HLA 
B*5101, HLA B*5102, HLA B*5103, HLA B*5201, HLA B*5801, 
HLA B60, HLA B61, HLA B7, HLA B*0702, HLA B8, HLA 
Cw*0301, HLA Cw*0401, HLA Cw*0602, HLA Cw*0702, HLA 
A*1101, HLA A3, HLA A*3101, HLA B*5401, HLA B*51, HLA 
B62HLA A*2402, HLA A*6801, HLA B*0702, HLA B*1402, HLA 
B*1501, HLA B*1510, HLA B*18, HLA B*2705, HLA B*2709, HLA 
B*3901, HLA B*3902, HLA B*4001, HLA B*4701, HLA B*4901, 
HLA B*0801, HLA B*0803, HLA B*0804, HLA B*0805, HLA B*39, 
HLA B*3903, HLA B*3905, HLA B*3906, HLA B*3907, HLA 
B*3908, HLA B*3910, HLA B*3911, HLA B*3913, HLA B*3915, 
HLA B*2702, HLA B*2703, HLA B*2704, HLA B*2706, HLA 
B*2707, HLA B*2711, HLA B*2714, HLA A*2402, HLA A*240201, 
HLA B*4402, HLA B*4404, HLA B*4404, HLA B*4405, HLA 
B*4406, HLA B*4407, HLA B*4408, HLA B*4410, HLA B*4415, 
HLA B*4426 
3 KFVAFLASK  FbpA 
(NMB0634) 
268 High 
Immunogenic 
94  HLA A1, HLA A*0201, HLA A*0205, HLA A24, HLA A*3302, HLA  
A 68.1, HLA A20, HLA A20Cw, HLA A2.1, HLA B14, HLA B*2702, 
HLA B*2705,HLA B*3501, HLA B*3701, HLA B*3801, HLA 
B*3901, HLA B*3902, HLA B40, HLA B*4403, HLA B*5101, HLA 
B*5102, HLA B*5103, HLA B*5201, HLA B*5801, HLA B60, HLA 
B61, HLA B7, Cw*0301, HLA Cw*0401, HLA Cw*0602, HLA 
Cw*0702, HLA A*1101, HLA A*3101, HLA B*62, HLA A*03, HLA 
A*01, HLA A*0201, HLA A*6801, HLA A*26, HLA B*08, HLA 
B*0702, HLA B*1402, HLA B*18, HLA B*5001, HLA A*0301, HLA 
A*0302, HLA A*2402, HLA A*240201, HLA A*2601, HLA A*2602, 
HLA A*2603, HLA A*2605, HLA A*2608, HLA A*2609, HLA 
A*2611, HLA A*2612, HLA A*2618, HLA B*2702, HLA B*2703, 
HLA B*2704, HLA B*2705, HLA B*2706, HLA B*2707, HLA 
B*2709, HLA B*2711, HLA B*2714, HLA B*39, HLA B*3901, HLA 
B*3902, HLA B*3903, HLA B*3905, HLA B*3906, HLA B*3907, 
HLA B*3908, HLA B*3910, HLA B*3911, HLA B*3913, HLA 
B*3915, HLA B*4402,HLA B*4404, HLA B*4404, HLA B*4405, 
HLA B*4406, HLA B*4407, HLA B*4408, HLA B*4410, HLA 
B*4415, HLA B*4426, HLA B*5802 
4 LVKVVSVQK FrpB 
(NMB1988) 
121 High 
Immunogenic 
99  HLA A1, HLA A2, HLA A*0201, HLA A*0205, HLA A24, HLA 
A*3302, HLA A68.1, HLA A20, HLA A20Cw, HLA A2.1, HLA B14, 
HLA B*2702, HLA B*2705,HLA B*3501, HLA B*3701, HLA 
B*3801, HLA B*3901, HLA B*3902, HLA B40, HLA B*4403, HLA 
B*5101, HLA-B*5102, HLA-B*5103, HLA-B*5201, HLA B60, HLA 
B61, HLA B7, HLA B8, HLA Cw*0301, HLA Cw*0401, HLA 
Cw*0602, HLA Cw*0702, HLA A*1101, HLA A*3101, HLA A3, 
HLA-B*5401, HLA-B*5301, HLA-B*51, HLA-B 62, HLA A*3301, 
HLA A 68.1, HLA A*1101, HLA-A*6801, HLA-B*0702, HLA 
B*1402, HLA B*1501, HLA B*1510, HLA B*2705, HLA A*0301, 
HLA A*0302, HLA A*0202, HLA A*0203, HLA A*0204, HLA 
A*0205, HLA A*0207, HLA A*0208, HLA A*0210, HLA A*0211, 
HLA A*0212, HLA A*0213, HLA A*0214, HLA A*0216, HLA 
A*0217, HLA A*0219, HLA A*0220, HLA A*0222, HLA A*0224, 
HLA A*0225, HLA A*0226, HLA A*0228, HLA A*0233, HLA 
A*0234, HLA A*0236, HLA A*0240, HLA A*0244, HLA A*0245, 
HLA A*0246, HLA A*2601, HLA A*2602, HLA A*2603, HLA 
A*2605, HLA A*2608, HLA A*2609, HLA A*2611, HLA A*2612, 
HLA A*2618, HLA B*0702, HLA B*0704, HLA B*0705, HLA 
B*0707, HLA B*0712, HLA B*0717, HLA B*0720, HLA B*0726, 
HLA B*4402, HLA B*4404, HLA B*4405, HLA B*4406, HLA 
B*4407, HLA B*4408, HLA B*4410, HLA B*4415, HLA B*4426, 
HLA B*5801, HLA B*5802 BIOINFORMATION  open access 
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5 KTVDAQDLLK  FrpB 
(NMB1988) 
148 High 
Immunogenic 
121  HLA A1, HLA A2, HLA A*0201, HLA A*0205, HLA A24, HLA 
A*3302, HLA A68.1, HLA A20, HLA A20Cw, HLA B14, HLA 
B*2702, HLA B*2705,HLA B*3501, HLA B*3701, HLA B*3801, 
HLA B*3901, HLA B*3902, HLA B40, HLA B*4403, HLA B*5101, 
HLA B*5102, HLA B*5103, HLA B*5201, HLA B*5801, HLA B60, 
HLA B61, HLA B7, HLA Cw*0301, HLA Cw*0401, HLA Cw*0602, 
HLA Cw*0702, HLA A*1101, HLA A*3101, HLA A3, HLA B*5401, 
HLA B*51, HLA B 62, HLA A*3301, HLA A*6801, HLA B*0702, 
HLA B*1402, HLA B*1501, HLA B*1510, HLA B*2705, HLA 
A*0203, HLA A*01, HLA A*03, HLA A*1101, HLA A*2402, HLA 
A*26, HLA A*6801, HLA B*08, HLA B*1402, HLA A*0201, HLA 
A*0202, HLA A*0203, HLA A*0204, HLA A*0205, HLA A*0207, 
HLA A*0208, HLA A*0210, HLA A*0211, HLA A*0212, HLA 
A*0213, HLA A*0214, HLA *0216, HLA A*0217, HLA A*0219, HLA 
A*0220, HLA A*0222, HLA A*0224, HLA A*0225, HLA A*0226, 
HLA A*0228, HLA A*0233, HLA A*0234, HLA A*0236, HLA 
A*0240, HLA A*0244, HLA A*0245, HLA A*0246, HLA A*0301, 
HLA A*0302, HLA A*2402, HLA A*240201, HLA A*2601, HLA 
A*2602, HLA A*2603, HLA A*2605, HLA A*2608, HLA A*2609, 
HLA A*2611, HLA A*2612, HLA A*2618, HLA B*0704, HLA 
B*0705, HLA B*0707, HLA B*0712, HLA B*0717, HLA B*0720, 
HLA B*0726, HLA B*0801, HLA B*0803, HLA B*0804, HLA 
B*0805, , HLA B*4402, HLA B*4403, HLA B*4404, HLA B*4405, 
HLA B*4406, HLA B*4407, HLA B*4408, HLA B*4410, HLA 
B*4415, HLA B*4426, HLA B*5802 
6 DAQDLLKGL FrpB 
(NMB1988) 
151 High 
Immunogenic 
113  HLA A1, HLA A2, HLA A*0201, HLA A*0205, HLA A24, HLA 
A*3302, HLA A68.1, HLA A20, HLA A20Cw, HLA B14, HLA 
B*2702, HLA B*2705,HLA B*3501, HLA B*3701, HLA B*3801, 
HLA B*3901, HLA B*3902, HLA B40, HLA B*4403, HLA B*5101, 
HLA B*5102, HLA B*5103, HLA B*5201, HLA B*5801, HLA B60, 
HLA B61, HLA B7, HLA B*0702, HLA B8, HLA Cw*0301, HLA 
Cw*0401, HLA Cw*0602, HLA Cw*0702, HLA A*1101, HLA A3, 
HLA A*3101, HLA B*5401,HLA B62, HLA A*0203, HLA B*3701, 
HLA B*3801, HLA B*3901, HLA B*3902, HLA B60, HLA A*03, 
HLA A*2402, HLA A*6801, HLA A*08, HLA A*1402, HLA A*2705, 
HLA A*0203, HLA B40,  HLA A*03, HLA A*2402, HLA A*26, HLA 
A*6801, HLA B*1402, HLA A*0202, HLA A*0204, HLA A*0205, 
HLA A*0207, HLA A*0208, HLA A*0210, HLA A*0211, 
HLAA*0212, HLA A*0213, HLA A*0214, HLA A*0216, HLA 
A*0217, HLA A*0219, HLA A*0220, HLA A*0222, HLA A*0224, 
HLA A*0225, HLA A*0226, HLA A*0228, HLA A*0233, HLA 
A*0234, HLA A*0236, HLA A*0240, HLA A*0244, HLA A*0245, 
HLA A*0246, HLA A*0301, HLA A*0302, HLA A*240201, HLA 
B*0702, HLA B*0704, HLA B*0705, HLA B*0707, HLA B*0712, 
HLA B*0717, HLA B*0720, HLA B*0726, HLA B*0801, HLA 
B*0803, HLA B*0804, HLA B*0805, HLA B*4402, HLA B*4403, 
HLA B*4404, HLA B*4405, HLA B*4406, HLA B*4407, HLA 
B*4408, HLA B*4410, HLA B*4415, HLA B*4426, HLA B*5802 
7 ATDMRELLK FrpB 
(NMB1988) 
60 High 
Immunogenic 
62  HLA A*01, HLA A*2402, HLA A*26, HLA B*2705, HLA A*0201, 
HLA A*0202, HLA A*0203, HLA A*0204, HLA A*0205, HLA 
A*0207, HLA A*0208, HLA A*0210, HLA A*0211, HLA A*0212, 
HLA A*0213, HLA A*0214, HLA A*0216, HLA A*0217, HLA 
A*0219, HLA A*0220, HLA A*0222, HLA A*0224, HLA A*0225, 
HLA A*0226, HLA A*0228, HLA A*0233, HLA A*0234, HLA 
A*0236, HLA A*0240, HLA A*0244, HLA A*0245, HLA A*0246, 
HLA B*0702, HLA B*0704, HLA B*0705, HLA B*0707, HLA 
B*0712, HLA B*0717, HLA B*0720, HLA B*0726,  HLA B*39, HLA 
B*3901, HLA B*3902, HLA B*3903, HLA B*3905, HLA B*3906, 
HLA B*3907, HLA-B*3908, HLA B*3909, HLA B*3910, HLA 
B*3911, HLA B*3913, HLA B*3915, HLA B*4402, HLA B*4403, 
HLA B*4404, HLA B*4405, HLA B*4406, HLA-B*4407, HLA 
B*4408, HLA B*4410, HLA B*4415 
8 HGKRGIISI  FrpB 
(NMB1988) 
488 Moderate 
Immunogenic 
81  HLA A1, HLA A2, HLA A*0201, HLA A*0205, HLA A24, HLA 
A*3302, HLA A68.1, HLA A20, HLA A20Cw, HLA A2.1, HLA B14, 
HLA B*2702, HLA B*2705,HLA B*3501, HLA B*3701, HLA 
B*3801, HLA B*3901, HLA B*3902, HLA B40, HLA B*4403, HLA 
B*5101, HLA B*5102, HLA B*5103, HLA B*5201, HLA B*5801, 
HLA B60, HLA B61, HLA B7, HLA B*0702, HLA B8, HLA 
Cw*0301, HLA Cw*0401, HLA Cw*0602, HLA Cw*0702, HLA 
A*1101, HLA A3, HLA A*3101, HLA B*5401, HLA B*51, HLA B62, 
HLA B*5201, HLA B*4402, HLA B*4501, HLA B*4701, HLA 
B*4901, HLA B*5001, HLA B*2709, HLA B*4101, HLA B*4001,  BIOINFORMATION  open access 
 
ISSN 0973-2063 (online) 0973-8894 (print)     
Bioinformation 6(7): 255-261 (2011)  261             © 2011 Biomedical Informatics
 
            HLA A*2402, HLA A*240201, HLA A*2601, HLA A*2602, HLA 
A*2603, HLA A*2605, HLA A*2608, HLA A*2609, HLA A*2611, 
HLA A*2612, HLA A*2618, HLA B*0702, HLA B*0704, HLA 
B*0705, HLA B*0707, HLA B*0712, HLA B*0717, HLA B*0720, 
HLA B*0726, HLA B*4404, HLA B*4405, HLA B*4406, HLA 
B*4407, HLA B*4408, HLA B*4410, HLA B*4415 
 
Table 5: List of MHC Class II T-cell epitopes with their corresponding HLA alleles, as predicted by Syfpeithi, nHLAPred, ProPred1, NetCTL and 
immunogenicity by POPI, showing the selected 12-mer epitope 
629VQKAVGSILVAG
640with high immunogenicity and that binds to maximum no. of HLA 
molecules from FrpB protein. 
Sl. 
No 
Epitope core 
(9-mer) 
Protein 
(Acc.no) 
Amino 
Acid 
position 
Immunogenicity 
as predicted by 
POPI server 
Total No 
of  
binding 
HLA  
molecules 
HLA alleles predicted to bind to the epitope 
1 KPYAKNSVALQAV  FbpA 
(NMB0634) 
192-204  High  42/51  HLA DRB1*0305, HLA DRB1*0306, HLA DRB1*0307, HLA 
DRB1*0308, HLA  DRB1*0309, HLA DRB1*0401, HLA 
DRB1*0402, HLA DRB1*0404, HLA DRB1*0405, HLA 
DRB1*0408, HLA DRB1*0410, HLA DRB1*0421, HLA 
DRB1*0423, HLA DRB1 *0426, HLA DRB1*0701, HLA 
DRB1*0703, HLA DRB1*0801, HLA DRB1*0802, HLA DRB1* 
0804, HLA DRB1*0806, HLA DRB1*0814, HLA DRB1*1106, 
HLA DRB1*1107, HLA DRB1* 1114, HLA DRB1*1121, HLA 
DRB1*1128, HLA DRB1*1302, HLA DRB1*1304, HLA DRB1* 
1305, HLA DRB1*1307, HLA DRB1*1311, HLA DRB1*1321, 
HLA DRB1*1322, HLA  DRB1*1323, HLA DRB1*1327, HLA 
DRB1*1328, HLA DRB1*1501, HLA DRB1*1502, HLA 
DRB1*1506, HLA DRB1*0101, HLA DRB1*0105, HLA 
DRB1*0102 
2 VQKAVGSILVAG FrpB 
(NMB1988) 
629-640  High  48/51  HLA DRB1*0101, HLA DRB1*0102, HLA DRB1*0301, HLA 
DRB1*0305, HLA DRB1*0306, HLA DRB1*0307, HLA 
DRB1*0308, HLA DRB1*0309, HLA DRB1*0311, HLA 
DRB1*0401, HLA DRB1*0402, HLA DRB1*0404, HLA 
DRB1*0405, HLA DRB1*0408, HLA DRB1*0421, HLA 
DRB1*0423, HLA DRB1*0426, HLA DRB1*0701, DRB1*0703, 
HLA DRB1*0801, HLA DRB1*0802, HLA DRB1*0804, HLA 
DRB1*0806, DRB1*0814, HLA DRB1*1106, HLA DRB1*1107, 
HLA DRB1*1114, HLA DRB1*1120, HLA DRB1*1121, HLA 
DRB1*1128, HLA DRB1*1301, HLA DRB1*1302, HLA 
DRB1*1304, HLA DRB1*1305, HLA DRB1*1307, HLA 
DRB1*1311, HLA DRB1*1321, HLA DRB1*1322, DRB1*1323, 
HLA DRB1*1327, HLA DRB1*1328, HLA DRB1*1501, HLA 
DRB1*1502, DRB1*1506, HLA DRB1*0101, HLA DRB1*0105, 
HLA DRB1*1505, HLA DRB1*1506 
 